ARS Pharmaceuticals, Inc.
SPRY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,023 | $522 | $341 | $192 |
| - Cash | $51 | $71 | $211 | $60 |
| + Debt | $0 | $0 | $0 | $9 |
| Enterprise Value | $972 | $451 | $131 | $141 |
| Revenue | $89 | $0 | $1 | $6 |
| % Growth | 297,063.3% | -97.7% | -76.1% | – |
| Gross Profit | $69 | $0 | $1 | $5 |
| % Margin | 76.9% | 100% | 100% | 96.1% |
| EBITDA | -$3 | -$67 | -$35 | -$19 |
| % Margin | -3.4% | -224,823.3% | -2,674.5% | -349.5% |
| Net Income | $8 | -$54 | -$35 | -$20 |
| % Margin | 9% | -181,216.7% | -2,635.4% | -367.7% |
| EPS Diluted | 0.078 | -0.57 | -0.87 | -0.7 |
| % Growth | 113.7% | 34.5% | -24.3% | – |
| Operating Cash Flow | $14 | -$59 | -$40 | -$18 |
| Capital Expenditures | -$1 | -$0 | -$0 | -$0 |
| Free Cash Flow | $13 | -$59 | -$40 | -$18 |